

# Stereoselective synthesis of *trans*-olefins by the copper-mediated S<sub>N</sub>2' reaction of vinyl oxazines with Grignard reagents. Asymmetric synthesis of *D*-*threo*-sphingosines

Om V. Singh and Hyunsoo Han\*

Department of Chemistry, The University of Texas at San Antonio, One UTSA Circle, San Antonio, TX 78249, USA

Received 29 November 2006; revised 22 January 2007; accepted 25 January 2007


Available online 30 January 2007

**Abstract**—The S<sub>N</sub>2' reaction of 6-vinyl-5,6-dihydro-4*H*-[1,3]oxazines with Grignard reagents in the presence of CuCN was studied, and high *trans* selectivity for the formation of double bond was observed with a variety of RMgX. The S<sub>N</sub>2' reaction, coupled with regioselective asymmetric aminohydroxylation reaction, provided a highly efficient route for the asymmetric synthesis of *D*-*threo*-*N*-acetylsphingosine.

© 2007 Elsevier Ltd. All rights reserved.

2-Vinylloxiranes,<sup>1</sup> 5-vinylloxazolines/oxazolidinones,<sup>2</sup> and 2-vinylaziridines<sup>3</sup> are versatile synthetic intermediates in organic synthesis, and have been extensively studied. These compounds have been shown to undergo a variety of different reactions, depending upon their structures, the nature of reagents used, and reaction conditions. For example, 2-vinylloxiranes react with alkyl lithiums in the presence of BF<sub>3</sub>·OEt<sub>2</sub><sup>1f</sup> or Grignard reagents<sup>1k</sup> to give the S<sub>N</sub>2 products, whereas their reactions with organocopper reagents afford the S<sub>N</sub>2' products.<sup>1i</sup> Also known is that 2-vinylloxiranes and 5-vinylloxazolines/oxazolidinones can react with transition metal complexes to form transition metal- $\pi$ -allyl intermediates, which in turn react with nucleophiles to furnish 'branched' and 'linear' products.<sup>1d,j,2</sup>

We recently reported a convenient route for the asymmetric synthesis of 6-vinyl-5,6-dihydro-4*H*-[1,3]oxazines **I**.<sup>4</sup> By comparing the structures of **I**, 2-vinylloxiranes, and 5-vinylloxazolines/oxazolidinones, it was noticed that they all shared two common structural features, the terminal vinyl group and the good leaving ability at the allylic position, and thus should exhibit similar reactivity patterns (reaction paths c–g, Fig. 1). In addition, after deprotonation by a base, **I** can react with



**Figure 1.** Potential reactions of the 6-vinyl-5,6-dihydro-4*H*-[1,3]oxazines **I**.

an electrophile to give a higher homolog (reaction path a in Fig. 1).<sup>5</sup> Compound **I** may also undergo a formal [3,3]-rearrangement to *N*-acetyl protected piperidine derivatives under appropriate reaction conditions (reaction path b in Fig. 1).<sup>6</sup> Despite such synthetic versatility, the chemistry of the vinyl oxazine **I** has not been explored much to date. In this Letter, we report the novel S<sub>N</sub>2' reaction of vinyl oxazines **I** with Grignard reagents in the presence of CuCN, which proceeds with high *trans* selectivity for double bond formation.<sup>7</sup> Also reported is an efficient asymmetric synthesis of *D*-*threo*-*N*-acetyl-sphingosine, which utilizes the developed S<sub>N</sub>2' reaction and regioselective asymmetric aminohydroxylation reaction<sup>8</sup> to stereoselectively introduce the requisite

**Keywords:** Sphingosine; Regioselective asymmetric aminohydroxylation; Oxazine; S<sub>N</sub>2' Reaction; Grignard reagents.

\* Corresponding author. Tel.: +1 210 458 4958; fax: +1 210 458 7428; e-mail: hyunsoo.han@utsa.edu

trans double bond and vicinal aminoalcohol functionalities, respectively.

As shown in Figure 2, the vinyl oxazines may exist in two conformers **I** and **I'**. Assuming that the reaction of the vinyl oxazines with soft nucleophiles proceeds through  $S_N2'$  mechanism, conformer **I** should lead to trans double bond formation, while cis double bond formation is expected from conformer **I'**. Due to steric repulsion between the terminal  $=CH_2$  group and  $R_2$  in conformer **I'**, conformer **I** would be more stable and thus more abundant in the equilibrium. Furthermore, attack of a soft nucleophile on conformer **I'** would be kinetically less favorable due to the steric hindrance between the  $R_2$  and the incoming nucleophile. Therefore, trans selectivity is anticipated from the reaction between the vinyl oxazines and soft nucleophiles such as Grignard reagents in the presence of CuCN.

Scheme 1 describes the asymmetric synthesis of vinyl oxazines **4–6**, which commenced with achiral  $\alpha,\beta$ -unsaturated ester **1**. Compound **1** was converted to the common synthetic precursor **2** for vinyl oxazines **4–6** according to the literature procedure, which included a





Figure 2. Cis and trans selectivities of the  $S_N2'$  reaction.



Scheme 1. Asymmetric synthesis of vinyl oxazines **4–6**.

four step reaction sequence of regioselective asymmetric aminohydroxylation, PMB-protection, DIBAL reduction, and vinylation.<sup>4</sup> Alcohol **2** was obtained as a 5:1 mixture of **3** and its C3 epimer. Treatment of **2** with mesyl chloride in the presence of excess triethylamine at 0 °C directly afforded oxazine **4**.

As a proof of our approach, the reaction of oxazine **4** with dodecylmagnesium bromide in the presence of 20 mol% (relative to the amount of the Grignard reagent used) CuCN was attempted. Gratifyingly, the reaction proceeded well to provide the protected *D-threo*-C<sub>18</sub>-sphingosine **7a** in a good yield and with a high trans:cis selectivity (~10:1) (Table 1, entry 1).<sup>9</sup> CuCN was found to be crucial for the reaction, since no reaction was observed in the absence of CuCN.

Next, it was reasoned that the stereochemistry at the allylic position (C6 of the oxazine ring) might also influence on the stereochemical outcome of the reaction. Thus, the optically pure vinyl oxazines **5** and **6** were prepared from alcohol **3**, which was obtained from **2** by column separation (Scheme 1). Refluxing **3** in the presence of a catalytic amount of *p*-toluenesulfonic acid in toluene furnished vinyl oxazine **5** with retention of the configuration at C6.<sup>4</sup> On the other hand, treatment of **3** with mesyl chloride and excess Et<sub>3</sub>N generated vinyl oxazine **6** with the inverted C6 configuration.<sup>4</sup> When vinyl oxazines **5** and **6** were subjected to the above reaction conditions, indeed, they showed different trans:cis selectivities in the formation of the protected *D-threo*-C<sub>18</sub>-sphingosine product, with **5** being more trans selective (>15:1) than **6** (~8:1) (Table 1, entries 2–3).


The different trans selectivities of two C6 epimeric vinyl oxazines **5** and **6** in the  $S_N2'$  reactions may be rationalized by considering the equilibria between conformers **VII** and **VII'** for **6**, and between conformers **VIII** and **VIII'** for **5** (Fig. 3). Due to steric repulsion caused by the *endo* terminal  $=CH_2$  group, conformers **VII** and **VIII** will be more stable than conformers **VII'** and **VIII'**

Table 1.  $S_N2'$  Reactions of vinyl oxazines **4–6** with Grignard reagents in the presence of CuCN in ethyl ether at 0 °C

Entry	Oxazines	Product	R=	Yields (%)	Trans:cis <sup>a</sup>
1	<b>4</b>	<b>7a</b>	$-(CH_2)_{11}CH_3$	82	~10:1
2	<b>6</b>	<b>7a</b>	$-(CH_2)_{11}CH_3$	80	8:1
3	<b>5</b>	<b>7a</b>	$-(CH_2)_{11}CH_3$	85	>15:1
4	<b>5</b>	<b>7b</b>	$-CH_2CH_3$	50	>15:1
5	<b>5</b>	<b>7c</b>	$-(CH_2)_4CH_3$	80	>15:1
6	<b>5</b>	<b>7d</b>	$-(CH_2)_9CH_3$	82	>15:1
7	<b>5</b>	<b>7e</b>	$-(CH_2)_{13}CH_3$	82	>15:1
8	<b>5</b>	—	$-CH(CH_3)_2$	NR <sup>b</sup>	

<sup>a</sup> The ratio of trans:cis was determined by the <sup>1</sup>H NMR of the reaction mixture.

<sup>b</sup> NR: no reaction.




**Figure 3.** A plausible explanation for the trans selectivity of the  $S_N2'$  reaction of the vinyl oxazines **5** and **6**.

**VIII'**. Such steric hindrance will be particularly severe in conformer **VIII'**, where both  $PMPOCH_2$ - and  $PMBO$ -groups are in close proximity to the *endo* terminal  $=CH_2$  group. This will shift the equilibrium for **5** toward conformer **VIII** more relative to the equilibrium for **6**. Moreover, approach of the nucleophile to conformers **VII'** and **VIII'** for the  $S_N2'$  reaction would be severely retarded due to the steric hindrance between the incoming nucleophile and the oxazine ring, and the up-stereochemistry of both  $PMPOCH_2$ - and  $PMBO$ -groups in conformer **VIII'** would further disfavor such approach of the nucleophile. Therefore, **5** should be more trans selective than **6**.

Now with the right C6 stereochemistry and reaction conditions established, the generality of the  $S_N2'$  reaction was examined with vinyl oxazine **5** and Grignard reagents with different chain length ( $C_2$ – $C_{14}$ ) in the presence of 20 mol %  $CuCN$ . As shown in Table 1, all linear chain Grignard reagents produced the corresponding protected *D-threo*-sphingosines (**7a–e**)<sup>10</sup> with excellent trans selectivities and good reaction yields (entries 3–7). However, a branched Grignard reagent failed to react (entry 8), and  $PhMgBr$  and vinyl- $MgBr$  did not react under the conditions. Use of other cuprate reagents such as Gilman's and higher-order cuprates, which contain branched alkyl groups, also proved to be fruitless.<sup>11</sup>

The developed  $S_N2'$  reaction can be easily applied to the asymmetric synthesis of sphingosines, which are ubiquitous membrane constituents of eukaryotic cells and have been reported to exhibit a variety of structural and regulatory functions.<sup>12,13</sup> Scheme 2 describes the asymmetric synthesis of *D-threo-N*-acetyl- $C_{18}$ -sphingosine (**8**). Thus, the trans selective  $S_N2'$  reaction of oxazine **5** with



**Scheme 2.** Asymmetric synthesis of *D-threo-N*-acetylsphingosine (**8**).

$C_{11}H_{23}MgBr$  in the presence of 20 mol %  $CuCN$  produced **7a**. Deprotection of both  $PMP$ - and  $PMB$ -groups by ceric ammonium nitrate ( $CAN$ )<sup>14</sup> in acetonitrile–water (4:1) provided *D-threo-N*-acetyl- $C_{18}$ -sphingosine (**8**), whose structure was confirmed by converting it to triacetate **9** and comparing with the corresponding known compound.<sup>15</sup> Finally, it is worthwhile mentioning that given the fact that the C3 stereochemistry of sphingosines can be easily controlled,<sup>16</sup> the corresponding *L-erythro-N*-acetyl- $C_{18}$ -sphingosine should be synthesized by applying the same synthetic route.

In conclusion, we have demonstrated that the reaction of the vinyl oxazines with Grignard reagents in the presence of  $CuCN$  proceeded via the  $S_N2'$  mechanism, and excellent trans selectivity for the formation of double bond was observed. Also described was that the developed  $S_N2'$  reaction, combined with the regioselective asymmetric aminohydroxylation reaction of olefins, could provide an efficient and convenient asymmetric route for the synthesis of sphingosine derivatives. Studies toward other possible reactions of the vinyl oxazines are currently under progress in our laboratory, and will be reported in due course.

### Acknowledgements

Financial support from National Institute of Health (GM 08194) and The Welch Foundation (AX-1534) is gratefully recognized.

### References and notes

- (a) Restorp, P.; Somfai, P. *Eur. J. Org. Chem.* **2005**, 3946–3951; (b) Smith, A. B.; Pitram, S. M.; Boldi, A. M.; Gaunt, M. J.; Sfougataki, C.; Moser, W. H. *J. Am. Chem. Soc.* **2003**, *125*, 14435–14445; (c) Equey, O.; Vrancken, E.; Alexakis, A. *Eur. J. Org. Chem.* **2004**, 2151–2159; (d) Trost, B. M.; Jiang, C. *J. Am. Chem. Soc.* **2001**, *123*, 12907–12908; (e) Bertozzi, F.; Crotti, P.; Macchia, F.; Pineschi, M.; Feringa, B. L. *Angew. Chem., Int. Ed.* **2001**, *40*, 930–932; (f) Alexakis, A.; Vrancken, E.; Mangeney, P.; Chemla, F. *J. Chem. Soc., Perkin Trans. 1* **2000**, 3352–3353; (g) Lipschutz, B. H.; Woo, K.; Gross, T.; Buzard, D. J.; Tirado, R. *Synlett* **1997**, 477–478; (h) Jung, M. E.; D'Amico, D. C. *J. Am. Chem. Soc.* **1995**, *117*, 7379–7388; For a review: (i) Marshall, J. A. *Chem. Rev.* **1989**, *89*, 1503–1511; (j) Tsuji, J.; Kataoka, H.; Kobayashi, Y. *Tetrahedron Lett.* **1981**, *22*, 2575–2578; (k) Herr, R. W.; Johnson, C. R. *J. Am. Chem. Soc.* **1970**, *92*, 4979–4981.
- (a) Cook, G. R.; Saraswathamma, M. *Tetrahedron Lett.* **2005**, *46*, 6491–6494; (b) Cook, G. R.; Yu, H.; Sankaranarayanan, S.; Shanker, P. S. *J. Am. Chem. Soc.* **2003**, *125*, 5115–5120; (c) Cook, G. R.; Pararajasingham, K. *Tetrahedron Lett.* **2002**, *43*, 9027–9029; (d) Oishi, S.; Niida, A.; Kamano, T.; Odagaki, Y.; Tamamura, H.; Otaka, A.; Hamanaka, H.; Fujii, N. *Org. Lett.* **2002**, *4*, 1055–1058; (e) Otaka, A.; Katagiri, F.; Kinoshita, T.; Odagaki, Y.; Oishi, S.; Tamamura, H.; Hamanaka, N.; Fujii, N. *J. Org. Chem.* **2002**, *67*, 6152–6161.
- (a) Cantrill, A. A.; Jarvis, A. N.; Osborn, H. M. I.; Ouadi, A.; Sweeney, J. B. *Synlett* **1996**, 847–849; (b) Tammura, H.; Yamashita, M.; Nakajima, Y.; Sakano, K.; Otaka, A.;

- Ohno, H.; Ibuka, T.; Fujii, N. *J. Chem. Soc., Perkin Trans. 1* **1999**, 2983–2996, and references cited therein; For a review: (c) Sweeney, J. B. *Chem. Soc. Rev.* **2002**, *31*, 247–258.
4. Singh, O. V.; Kampf, D. J.; Han, H. *Tetrahedron Lett.* **2004**, *45*, 7239–7242.
5. (a) Toshimitsu, A.; Terao, K.; Uemura, S. *J. Org. Chem.* **1987**, *52*, 2018–2026; (b) Adickes, H. W.; Politzer, I. R.; Meyers, A. I. *J. Am. Chem. Soc.* **1969**, *91*, 2155–2156.
6. (a) Wang, C.-L. J.; Calabresse, J. C. *J. Org. Chem.* **1991**, *56*, 4341–4343; (b) Overman, L. E. *Angew. Chem., Int. Ed. Engl.* **1984**, *23*, 579–586; (c) Knapp, S.; Patel, D. V. *Tetrahedron Lett.* **1982**, *23*, 3539–3542.
7. For a review of  $S_N2'$  reactions: Kar, A.; Argade, N. P. *Synthesis* **2005**, 2995–3022.
8. (a) Han, H.; Cho, C. W.; Janda, K. D. *Chem. Eur. J.* **1999**, *5*, 1565–1569; see, for other similar approaches: (b) Morgan, A. J.; Masse, C. E.; Panek, J. S. *Org. Lett.* **1999**, *1*, 1949–1952; (c) Chuang, C.-C.; Vassar, V.; Ma, Z.; Geney, R.; Ojima, I. *Chirality* **2002**, *14*, 151–162; For initial studies: (d) Li, G.; Chang, H.-T.; Sharpless, K. B. *Angew. Chem., Int. Ed.* **1996**, *35*, 451–454; (e) Rudolph, J.; Sennhenn, P. C.; Vlaar, C. P.; Sharpless, K. B. *Angew. Chem., Int. Ed.* **1996**, *35*, 2810–2813; (f) Bruncko, M.; Schlingloff, G.; Sharpless, K. B. *Angew. Chem., Int. Ed.* **1997**, *36*, 1483–1486.
9. *General procedure for the copper-mediated  $S_N2'$  reaction of vinyl oxazine with Grignard reagents:* A flame dried two-necked flask was charged with cuprous cyanide (8.5 mg, 0.1 mmol) and dry ether (10 mL) under nitrogen atmosphere. The reaction flask was cooled to 0 °C in ice-salt mixture and a solution of Grignard reagent in ether (1 M, 0.5 mL, 0.5 mmol) was added dropwise. After stirring for 10 min, a solution of vinyl oxazine (79 mg, 0.2 mmol) in ether was added dropwise through cannula for 10 min. The reaction mixture was stirred for an additional hour, and then brought to room temperature and stirred for another 1 h. After the complete disappearance of the starting material on TLC, the brownish reaction mixture was quenched with saturated ammonium chloride, extracted with ethyl ether (3 × 20 mL), washed with water, and dried over anhydrous sodium sulfate. The solvents were removed in vacuo and the residue was purified by flash column chromatography on silica gel (ethyl acetate-hexane, 3:1) to afford the respective protected *N*-acetyl-sphingosines **7a–e**.
10. *Characterization data 7a:* Mp = 62–63 °C;  $[\alpha]_D^{25}$  –44.5 (c 1.2, CHCl<sub>3</sub>); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.18 (d, 2H, *J* = 9.0 Hz), 6.82–6.81 (m, 6H), 5.86 (d, 1H, *J* = 8.6 Hz), 5.73 (dt, 1H, *J* = 7.0, 16.0 Hz), 5.41 (dd, 1H, *J* = 8.0, 15.6 Hz), 4.53 (d, 1H, *J* = 10.5 Hz), 4.31–4.25 (m, 2H), 4.13 (dd, 1H, *J* = 3.0, 8.0 Hz), 3.97–3.90 (m, 2H), 3.78 (s, 3H), 3.77 (s, 3H), 2.07 (q, 2H, *J* = 7.4 Hz), 1.99 (s, 3H), 1.44–1.35 (m, 2H), 1.26 (s, 20H), 0.88 (t, 3H, *J* = 6.7 Hz); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 169.78, 159.29, 154.05, 152.78, 135.99, 130.29, 129.43, 126.60, 115.64, 114.67, 113.78, 70.04, 66.84, 55.67, 55.14, 52.28, 32.24, 31.84, 29.59, 29.42, 29.14, 23.15, 22.57, 13.93. *Compound 7b:*  $[\alpha]_D^{25}$  –50.0 (c 1.3, CH<sub>2</sub>Cl<sub>2</sub>); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.18 (d, 2H, *J* = 9.0 Hz), 6.82–6.80 (m, 6H), 5.88 (d, 1H, *J* = 8.8 Hz), 5.73 (dt, 1H, *J* = 6.4, 15.4 Hz), 5.42 (dd, 1H, *J* = 7.6, 15.6 Hz), 4.54 (d, 1H, *J* = 11.5 Hz), 4.32–4.25 (m, 2H), 4.14 (dd, 1H, *J* = 3.0, 8.0 Hz), 3.97–3.91 (m, 2H), 3.77 (s, 3H), 3.76 (s, 3H), 2.08–2.04 (m, 2H), 1.99 (s, 3H), 1.42 (d hexate, 2H, *J* = 1.5, 7.0 Hz), 0.91 (t, 3H, *J* = 7.0 Hz); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 169.77, 159.29, 154.05, 152.78, 135.61, 130.29, 129.43, 126.88, 115.64, 114.69, 113.80, 76.69, 70.06, 66.86, 55.69, 55.15, 52.30, 34.29, 23.18, 22.25, 13.49. *Compound 7c:* mp = 40–41 °C;  $[\alpha]_D^{25}$  –59.7 (c 1.3, CH<sub>2</sub>Cl<sub>2</sub>); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.18 (d, 2H, *J* = 8.5 Hz), 6.82–6.80 (m, 6H), 5.87 (d, 1H, *J* = 8.7 Hz), 5.73 (dt, 1H, *J* = 6.5, 15.4 Hz), 5.41 (dd, 1H, *J* = 8.5, 15.6 Hz), 4.53 (d, 1H, *J* = 12 Hz), 4.32–4.25 (m, 2H), 4.13 (dd, 1H, *J* = 3.0, 8.5 Hz), 3.97–3.90 (m, 2H), 3.77 (s, 3H), 3.76 (s, 3H), 2.11–2.04 (m, 2H), 1.99 (s, 3H), 1.40–1.35 (m, 2H), 1.32–1.25 (m, 6H), 0.89 (t, 3H, *J* = 6.8 Hz); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 169.80, 159.32, 154.10, 152.83, 136.00, 130.35, 129.46, 126.68, 115.69, 114.72, 113.83, 76.77, 70.09, 66.89, 55.72, 55.20, 52.33, 32.27, 31.64, 29.12, 28.79, 23.23, 22.55, 13.98. *Compound 7d:* mp = 49–50 °C;  $[\alpha]_D^{25}$  –46.89 (c 1.22, CH<sub>2</sub>Cl<sub>2</sub>); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.18 (d, 2H, *J* = 8.9 Hz), 6.82–6.81 (m, 6H), 5.85 (d, 1H, *J* = 8.7 Hz), 5.73 (dt, 1H, *J* = 6.0, 15.5 Hz), 5.41 (dd, 1H, *J* = 8.1, 15.6 Hz), 4.53 (d, 1H, *J* = 11.3 Hz), 4.31–4.25 (m, 2H), 4.13 (dd, 1H, *J* = 3.0, 8.0 Hz), 3.97–3.90 (m, 2H), 3.78 (s, 3H), 3.76 (s, 3H), 2.07 (q, 2H, *J* = 7.2 Hz), 1.99 (s, 3H), 1.41–1.35 (m, 2H), 1.26 (s, 16H), 0.88 (t, 3H, *J* = 6.8 Hz); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 169.97, 159.17, 153.88, 152.63, 136.24, 130.16, 129.53, 129.40, 126.39, 115.49, 114.54, 113.72, 69.93, 66.57, 55.67, 55.19, 52.18, 32.34, 31.90, 29.64, 29.48, 29.35, 29.17, 23.36, 22.67, 14.11. *Compound 7e:* mp = 67–68 °C;  $[\alpha]_D^{25}$  –40.5 (c 1.2, CH<sub>2</sub>Cl<sub>2</sub>); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.18 (d, 2H, *J* = 8.2 Hz), 6.82–6.81 (m, 6H), 5.84 (d, 1H, *J* = 8.5 Hz), 5.73 (dt, 1H, *J* = 6.7, 15.5 Hz), 5.41 (dd, 1H, *J* = 7.6, 15.6 Hz), 4.53 (d, 1H, *J* = 11.0 Hz), 4.31–4.25 (m, 2H), 4.13 (dd, 1H, *J* = 3.0, 7.5 Hz), 3.97–3.90 (m, 2H), 3.78 (s, 3H), 3.77 (s, 3H), 2.07 (q, 2H, *J* = 7.4 Hz), 1.99 (s, 3H), 1.41–1.35 (m, 2H), 1.26 (s, 24H), 0.88 (t, 3H, *J* = 6.5 Hz); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 169.81, 159.35, 154.12, 152.84, 136.07, 130.37, 129.49, 126.67, 115.70, 114.75, 113.86, 76.79, 70.12, 66.91, 55.75, 55.23, 52.34, 32.32, 31.92, 29.69, 29.50, 29.22, 23.28, 22.67, 14.03.
11. (a) Lipshutz, B. H. *Synlett* **1990**, 119–128; (b) Spino, C.; Beaulieu, C.; Lafreniere, J. J. *Org. Chem.* **2000**, *65*, 7091–7097.
12. For the biological activities of sphingosines: (a) Merrill, A. H., Jr.; Sweeley, C. C. In *Biochemistry of Lipids, Lipoproteins and Membranes*; Vance, D. E., Vance, J. E., Eds.; Elsevier Science B.V.: Amsterdam, 1996; Chapter 12, pp 309–339; (b) Kolter, T.; Sandhoff, K. *Angew. Chem. Int. Ed.* **1999**, *38*, 1532–1568; (c) Hannun, Y. A. *Sphingolipid-Mediated Signal Transduction*; R.G. Landes Company: Austin, 1997.
13. For reviews on the synthesis of sphingosines: (a) Koskinen, P. M.; Koskinen, A. M. P. *Synthesis* **1998**, 1075–1091; (b) Vankar, Y. D.; Schmidt, R. R. *Chem. Soc. Rev.* **2000**, *29*, 201–216; For more recent syntheses: (c) Chaudhari, V. D.; Kumar, K. S. A.; Dhavale, D. D. *Org. Lett.* **2005**, *7*, 5805–5807; (d) Rai, A. N.; Basu, A. *Org. Lett.* **2004**, *6*, 2861–2863; (e) Torssell, S.; Somfai, P. *Org. Biomol. Chem.* **2004**, *2*, 1643–1646; (f) Raghavan, S.; Rajender, A.; Yadav, J. S. *Tetrahedron: Asymmetry* **2003**, *14*, 2093–2099.
14. (a) Wright, J. A.; Yu, J.; Spencer, J. B. *Tetrahedron Lett.* **2001**, *42*, 4033–4036; (b) Oikawa, Y.; Yoshioka, T.; Yonemitsu, O. *Tetrahedron Lett.* **1982**, *23*, 885–888; (c) Fukuyama, T.; Laird, A. A.; Hotchkiss, L. M. *Tetrahedron Lett.* **1985**, *26*, 6291–6292.
15. Shibuya, H.; Kawashima, K.; Ikeda, M.; Kitagawa, I. *Tetrahedron Lett.* **1989**, *30*, 7205–7208.
16. Singh, O. V.; Han, H. *Tetrahedron Lett.* **2003**, *44*, 5289–5292.